Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
131 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Download search resultsDownload the search results for:
"HIV Preventive Vaccine" [CONDITION] (131 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Lentivirus Infections;   Retroviridae Infections;   RNA Virus Infections;   Virus Diseases;   Sexually Transmitted Diseases, Viral;   Sexually Transmitted Diseases;   Immunologic Deficiency Syndromes;   Immune System Diseases;   Slow Virus Diseases
Interventions: Procedure: Circumcision;   Procedure: Flexible sigmoidoscopy
3 Unknown  Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
Condition: HIV Infections
Intervention: Biological: Experimental
4 Completed A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
Condition: HIV Infection
Interventions: Drug: Vaccination;   Drug: Placebo
5 Completed Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
6 Active, not recruiting Antigenic Competition in HIV Preventive Vaccines
Condition: HIV Infections
Interventions: Biological: rAd5 Gag-Pol Env A/B/C;   Biological: rAd5 Gag-Pol
7 Active, not recruiting Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad26.ENVA.01 (rAd26);   Biological: Placebo Vaccine
8 Active, not recruiting Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rAd35 Env A;   Biological: rAd5 Env A;   Biological: rAd5 Env B
9 Completed Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins
Condition: HIV Infections
Interventions: Biological: HIV-1 DNA plasmid vaccine;   Biological: HIV-1 recombinant Ad5 vaccine
10 Completed Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
Conditions: HIV Infections;   H1N1 Influenza
Intervention: Biological: Arepanrix
11 Completed Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-B;   Biological: IL-12 DNA plasmids
12 Completed Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
13 Unknown  Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
14 Active, not recruiting Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
15 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
16 Active, not recruiting Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine;   Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine;   Biological: DNA vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
17 Completed Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
Condition: HIV Infections
Interventions: Biological: pGA2/JS7 DNA vaccine;   Biological: Placebo;   Biological: MVA/HIV62 vaccine
18 Completed Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
Condition: HIV Infections
Interventions: Biological: DNA Vaccine;   Biological: DNA Vaccine placebo;   Biological: rAd35;   Biological: rAd35 placebo;   Biological: rAd5;   Biological: rAd5 placebo
19 Recruiting Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Conditions: HIV Infection;   HIV Seronegativity
Intervention:
20 Active, not recruiting Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
Condition: HIV Infections
Intervention: Biological: Ad5.ENVA.48 HIV-1 vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years